BALTIMORE (Reuters) - A U.S. Medicare advisory panel on Wednesday expressed doubts that industry-sponsored data on the use of PET scans to diagnose and evaluate nine cancers could apply more widely to other cancers.
BALTIMORE (Reuters) - A U.S. Medicare advisory panel on Wednesday expressed doubts that industry-sponsored data on the use of PET scans to diagnose and evaluate nine cancers could apply more widely to other cancers.
